Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study
| العنوان: | Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study |
|---|---|
| المؤلفون: | Milos Opravil, Heiner C. Bucher, Hansjakob Furrer, Andri Rauch, Enos Bernasconi, Pietro Vernazza, Bernard Hirschel, Matthias Cavassini, Mathew Simcock, Luigia Elzi, Christoph A Fux |
| المصدر: | Antiviral Therapy, Vol. 13, No 8 (2008) pp. 1077-1082 |
| بيانات النشر: | SAGE Publications, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, HIV Infections/ drug therapy, Anti-HIV Agents, Organophosphonates, Renal function, HIV Infections, Gastroenterology, Bone resorption, Bone remodeling, Cohort Studies, Alkaline Phosphatase/ blood, Adenine/adverse effects/ analogs & derivatives/therapeutic use, Switzerland/epidemiology, Interquartile range, Internal medicine, medicine, Anti-HIV Agents/adverse effects/therapeutic use, Humans, Pharmacology (medical), Tenofovir, ddc:616, Pharmacology, Bone mineral, Phosphonic Acids/ adverse effects/ therapeutic use, Osteomalacia, business.industry, Adenine, Middle Aged, Alkaline Phosphatase, medicine.disease, Surgery, Infectious Diseases, Cohort, Toxicity, Female, business, Switzerland |
| الوصف: | BackgroundTenofovir (TDF) use has been associated with proximal renal tubulopathy, reduced calculated glomerular filtration rates (cGFR) and losses in bone mineral density. Bone resorption could result in a compensatory osteoblast activation indicated by an increase in serum alkaline phosphatase (sAP). A few small studies have reported a positive correlation between renal phosphate losses, increased bone turnover and sAP.MethodsWe analysed sAP dynamics in patients initiating ( n=657), reinitiating ( n=361) and discontinuing ( n=73) combined antiretroviral therapy with and without TDF and assessed correlations with clinical and epidemiological parameters.ResultsTDF use was associated with a significant increase of sAP from a median of 74 U/l (interquartile range 60–98) to a plateau of 99 U/l (82–123) after 6 months ( PConclusionsWe document a highly significant association between TDF use and increased sAP in a large observational cohort. The lack of correlation between TDF use and sALT suggests that the increase in sAP is because of the bone isoenzyme and indicates stimulated bone turnover. This finding, together with published data on TDF-related renal phosphate losses, this finding raises concerns that TDF use could result in osteomalacia with a loss in bone mineral density at least in a subset of patients. This potentially severe long-term toxicity should be addressed in future studies. |
| تدمد: | 2040-2058 1359-6535 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5ea81ca2716a46d40a112c3b1b8bdfaTest https://doi.org/10.1177/135965350801300803Test |
| حقوق: | RESTRICTED |
| رقم الانضمام: | edsair.doi.dedup.....a5ea81ca2716a46d40a112c3b1b8bdfa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20402058 13596535 |
|---|